Sort
10,766 grants matching “checkpoint inhibitor”
TRAIL-induced Cell Death in Breast Cancer Cells
$784,437Stanley Lipkowitz · Division Of Clinical Sciences - Nci · ZIA · FY2016 · CA
Chemoenzymatic glycan editing for deciphering biological functions of glycans
$783,616Peng Wu · Scripps Research Institute, The · R35 · FY2021 · GM
Regulation of the osmoprotective transcription factor NFAT5
$783,103Maurice Benjam Burg · National Heart, Lung, And Blood Institute · ZIA · FY2012 · HL
PROJECT 1: TIME-Based Spatiotemporal Cancer Immunograms Predictive for Immunotherapy-Targeted Therapy Sequential Combinations
$782,862James R. Heath · Institute For Systems Biology · U54 · FY2025 · CA
AGR2-superantigen vaccine conjugate for the treatment of pancreaticductal adenocarcinoma
$782,691Reeder McNeil Robinson · Leukogene Therapeutics, Inc. · R44 · FY2023 · CA
Immune Regulation of COVID-19 Infection in Cancer and Autoimmunity
$781,552Madhav V Dhodapkar · Emory University · U54 · FY2020 · CA
Optimizing Anti-NMDAR Antibodies for Triple-Negative Breast Cancer Therapy
$781,436Tobias Janowitz · Cold Spring Harbor Laboratory · R01 · FY2025 · CA
Development of polymeric synthetic biomaterial IP-001 to potentiate asystemic immunotherapy of hepatocellular carcinoma via thermal ablation
$780,148Siu Kit Lam · Immunophotonics, Inc. · R44 · FY2024 · CA
Signal Transduction Events and the Regulation of Cell Growth
$780,073Jane B Trepel · Division Of Clinical Sciences - Nci · ZIC · FY2018 · CA
Targeting the BCL2 immune checkpoint to enhance the immunostimulatory effects of radiation in breast cancer
$779,894Lorenzo Galluzzi · Research Inst Of Fox Chase Can Ctr · R01 · FY2025 · CA
Human Immune Responses to Tumor Antigens for Cancer Immunotherapy
$779,653Jeffrey Schlom · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
Live cell reporters of genetic changes in stiff vs soft surroundings - Causes & Consequences
$778,993Dennis E. Discher · University Of Pennsylvania · U01 · FY2023 · CA
Chemoenzymatic glycan editing for deciphering biological functions of glycans
$778,432Peng Wu · Scripps Research Institute, The · R35 · FY2025 · GM
Chemoenzymatic glycan editing for deciphering biological functions of glycans
$778,432Peng Wu · Scripps Research Institute, The · R35 · FY2024 · GM
Developing CVD prediction models for women with early stage breast cancer
$777,704Heather A Greenlee · Fred Hutchinson Cancer Center · U01 · FY2025 · CA
Preclinical toxicology and pharmacology evaluation of a newTNFR2 antagonistic monoclonal antibody for CTCL therapy
$776,973Kenneth Olivier · Boston Immune Technologies And Therapeutics, Inc. · R44 · FY2024 · CA
Targeting the immunosuppressive tumor microenvironment to enhance efficacy of radiotherapy and immuno-radiotherapy for oral cancer
$776,961Andrew Sikora · Baylor College Of Medicine · U01 · FY2019 · DE
Regulation of PDAC metabolism and immunity by collagen and its cleavage products
$776,779Michael Karin · University Of California, San Diego · U01 · FY2024 · CA
Clinical Translation of a Novel Diagnostic Agent to Predict Immunotherapy Response in Solid Tumors
$774,682James F Kronauge · Cytosite Biopharma, Inc. · R44 · FY2020 · CA
Targeting Genetic and Metabolic Alterations in Distinct Subtypes of RCC
$774,077Ramaprasad Srinivasan · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
A Targeted Approach to Treat Immunotherapy-Induced Myocarditis with CXCR3 Blockade
$773,843Han Zhu · Stanford University · R01 · FY2025 · HL
Targeting DNA damage repair and related pathways in HRD-womens cancers
$773,642Jung-Min Lee · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA
Targeting the mutant promoter of Telomerase Reverse Transcriptase (TERT)
$772,180Dan Theodorescu · Cedars-Sinai Medical Center · R01 · FY2023 · CA
PROJECT 1: TIME-Based Spatiotemporal Cancer Immunograms Predictive for Immunotherapy-Targeted Therapy Sequential Combinations
$772,064James R. Heath · Institute For Systems Biology · U54 · FY2024 · CA
Optoacoustic Imaging Scanner
$771,626Zaver M Bhujwalla · Johns Hopkins University · S10 · FY2020 · OD